Normunity: $75 Million (Series B) Raised For Broadening Pipeline Of Novel Anti-Cancer Therapies
By Amit Chowdhry ● Yesterday at 8:25 AM
Normunity, a biotechnology company creating novel anti-cancer therapies, announced today that it closed a Series B funding round of $75 million. The funding was co-led by Samsara BioCapital and Enavate Sciences, alongside other new investors Regeneron Ventures, Pfizer Ventures and YK Bioventures, as well as existing investors Canaan Partners, Sanofi Ventures, Taiho Ventures, Osage Venture Partners, HongShan Capital Group, and Connecticut Innovations. And the Board of Directors will be expanded to include David Parry, PhD (Samsara), Sara Nayeem, MD (Enavate), and Marie-Clare Peakman, MD (Pfizer Ventures).